An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer

Genes Chromosomes and Cancer

Volumn 52, Issue 9, 2013, Pages 860-871

  di Martino, Erica ^a   Taylor, Claire F ^b   Roulson, Jo An ^a   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; BLADDER CANCER; BLADDER EPITHELIUM; CANCER CELL CULTURE; CANCER STAGING; CHROMOSOME 4P; DOWN REGULATION; EPIGENETICS; GENE DELETION; GENE FREQUENCY; GENE TARGETING; GENETIC POLYMORPHISM; GENOME; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 4; DOWN-REGULATION; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SEQUENCE DELETION; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84880510897     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22082     Document Type: Article

References (44)

1. Adar R, Monsonego-Ornan E, David P, Yayon A. 2002. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 17:860-868.
2. Ahmad I, Iwata T, Leung HY. 2012. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 1823:850-860.
3. Beder LB, Gunduz M, Ouchida M, Fukushima K, Gunduz E, Ito S, Sakai A, Nagai N, Nishizaki K, Shimizu K. 2003. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 83:99-105.
4. Bell SM, Shaw M, Jou YS, Myers RM, Knowles MA. 1997. Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Genomics 44:163-170.
5. Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA. 2006. Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 25:5037-5045.
6. di Martino E, L'Hote CG, Kennedy W, Tomlinson DC, Knowles MA. 2009. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 28:4306-4316.
7. Elder PA, Bell SM, Knowles MA. 1994. Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4p16.3. Oncogene 9:3433-3436.
8. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. 2000. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60:4894-4906.
9. Goebell PJ, Knowles MA. 2010. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 28:409-428.
10. Henrich KO, Schwab M, Westermann F. 2012. 1p36 tumor suppression-A matter of dosage? Cancer Res 72:6079-6088.
11. Hu N, Roth MJ, Polymeropolous M, Tang ZZ, Emmert-Buck MR, Wang QH, Goldstein AM, Feng SS, Dawsey SM, Ding T, Zhuang ZP, Han XY, Ried T, Giffen C, Taylor PR. 2000. Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese population. Genes Chromosomes Cancer 27:217-228.
12. Hutton KA, Trejdosiewicz LK, Thomas DF, Southgate J. 1993. Urothelial tissue culture for bladder reconstruction: An experimental study. J Urol 150:721-725.
13. Jiao Y-F, Sugai T, Habano W, Uesugi N, Takagane A, Nakamura S-i. 2006. Clinicopathological significance of loss of heterozygosity in intestinal- and solid-type gastric carcinomas: A comprehensive study using the crypt isolation technique. Mod Pathol 19:548-555.
14. Kim I, Moon S, Yu K, Kim U, Koh GY. 2001. A novel fibroblast growth factor receptor-5 preferentially expressed in the pancreas. Biochim Biophys Acta 1518:152-156.
15. Klint P, Claesson-Welsh L. 1999. Signal transduction by fibroblast growth factor receptors. Front Biosci 4:D165-177.
16. Knowles MA. 1999. Identification of novel bladder tumour suppressor genes. Electrophoresis 20:269-279.
17. Knowles MA. 2008. Novel therapeutic targets in bladder cancer: Mutation and expression of FGF receptors. Future Oncol 4:71-83.
18. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. 1994. Allelotype of human bladder cancer. Cancer Res 54:531-538.
19. Knudson AG, Jr. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
20. LopezJimenez N, Gerber S, Popovici V, Mirza S, Copren K, Ta L, Shaw GM, Trueb B, Slavotinek AM. 2010. Examination of FGFRL1 as a candidate gene for diaphragmatic defects at chromosome 4p16.3 shows that Fgfrl1 null mice have reduced expression of Tpm3, sarcomere genes and Lrtm1 in the diaphragm. Hum Genet 127:325-336.
21. Mostofi FK, Davies CJ, Sesterhenn I. 1999. Histological Typing of Urinary Bladder Tumours. Berlin, Heidlelberg, New York: Springer-Verlag.
22. Ning Y, Weber JL, Killary AM, Ledbetter DH, Smith JR, Pereira-Smith OM. 1991. Genetic analysis of indefinite division in human cells: Evidence for a cell senescence-related gene(s) on human chromosome 4. Proc Natl Acad Sci USA 88:5635-5639.
23. Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D. 1995. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 55:5396-5399.
24. Powers CJ, McLeskey SW, Wellstein A. 2000. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7:165-197.
25. Rieckmann T, Kotevic I, Trueb B. 2008. The cell surface receptor FGFRL1 forms constitutive dimers that promote cell adhesion. Exp Cell Res 314:1071-1081.
26. Rieckmann T, Zhuang L, Fluck CE, Trueb B. 2009. Characterization of the first FGFRL1 mutation identified in a craniosynostosis patient. Biochim Biophys Acta 1792:112-121.
27. Santarosa M, Ashworth A. 2004. Haploinsufficiency for tumour suppressor genes: When you don't need to go all the way. Biochim Biophys Acta 1654:105-122.
28. Schild C, Trueb B. 2005. Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors. Int J Mol Med 16:1169-1173.
29. Shivapurkar N, Sood S, Wistuba II, Virmani AK, Maitra A, Milchgrub S, Minna JD, Gazdar AF. 1999. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res 59:3576-3580.
30. Shivapurkar N, Maitra A, Milchgrub S, Gazdar AF. 2001. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol 32:169-177.
31. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, Murison JG. 2001. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271:171-182.
32. Sobin LH, Gospodarowicz MK, Wittekind C. 2010. TNM Classification of Malignant Tumours. 7th ed. Oxford: Wiley-Blackwell.
33. Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. 1994. Normal human urothelial cells in vitro: Proliferation and induction of stratification. Lab Invest 71:583-594.
34. Steinberg F, Gerber SD, Rieckmann T, Trueb B. 2010a. Rapid fusion and syncytium formation of heterologous cells upon expression of the FGFRL1 receptor. J Biol Chem 285:37704-37715.
35. Steinberg F, Zhuang L, Beyeler M, Kalin RE, Mullis PE, Brandli AW, Trueb B. 2010b. The FGFRL1 receptor is shed from cell membranes, binds fibroblast growth factors (FGFs), and antagonizes FGF signaling in Xenopus embryos. J Biol Chem 285:2193-2202.
36. Tomlinson DC, Hurst CD, Knowles MA. 2007. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26:5889-5899.
37. Trueb B, Taeschler S. 2006. Expression of FGFRL1, a novel fibroblast growth factor receptor, during embryonic development. Int J Mol Med 17:617-620.
38. Trueb B, Zhuang L, Taeschler S, Wiedemann M. 2003. Characterization of FGFRL1, a novel fibroblast growth factor (FGF) receptor preferentially expressed in skeletal tissues. J Biol Chem 278:33857-33865.
39. Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G. 2011. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem 286:420-428.
40. Wiedemann M, Trueb B. 2000. Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. Genomics 69:275-279.
41. Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, Zender L, Wang XW, Powers S, Wigler M, Lowe SW. 2012. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci USA 109:8212-8217.
42. Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C, Johnston C. 2001. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 194:27-34.
43. Zheng H-T, Jiang L-X, Lv Z-C, Li D-P, Zhou C-Z, Gao J-J, He L, Peng Z-H. 2008. Are there tumor suppressor genes on chromosome 4p in sporadic colorectal carcinoma? World J Gastroenterol 14:90-94.
44. Zhuang L, Villiger P, Trueb B. 2011. Interaction of the receptor FGFRL1 with the negative regulator Spred1. Cell Signal 23:1496-1504.